Order Article Reprints

Zhang Z, Diao P, Zhang X, Nakajima T, Kimura T, Tanaka N. Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice. Biomedicines. 2022; 10(7):1667. https://doi.org/10.3390/biomedicines10071667

Zhang, Zhe, Pan Diao, Xuguang Zhang, Takero Nakajima, Takefumi Kimura, and Naoki Tanaka. 2022. "Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice" Biomedicines 10, no. 7: 1667. https://doi.org/10.3390/biomedicines10071667

Zhang, Z., Diao, P., Zhang, X., Nakajima, T., Kimura, T., & Tanaka, N. (2022). Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice. Biomedicines, 10(7), 1667. https://doi.org/10.3390/biomedicines10071667